ArticleBMC medical genomics2022

SYNJ2 is a novel and potential biomarker for the prediction and treatment of cancers: from lung squamous cell carcinoma to pan-cancer.

Wei Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.